Infections Infections, Sepsis, Bacteremia
Conditions
Interventions
Disinfect the puncture site with 1.5% oranexidine once for 30 seconds before collecting blood culture.
Anti-Infective Agents
disinfection, sterilization
Sponsors
Ota Kohei
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. over 18 years 2. Patients from whom blood culture was collected in the emergency department or the intensive care unit 3. Provision of written informed consent from patients or their surrogate
Exclusion criteria
Exclusion criteria: 1. History of allergy or contact dermatitis caused by 1.5% oranexidine (for those who have already been enrolled in this study, including those who have been found to have adverse events in this study for which a causal relationship with 1.5% oranexidine cannot be denied.) 2. Patients with systemic skin diseases 3. Patients with wound or skin ulcer at the puncture site 4. Patients whose puncture site is contaminated with feces, urine, or sludge, and who require procedures other than disinfection such as wiping. 5. Patients who have received antimicrobial agents with antimicrobial activity against contaminating bacteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Contamination rate of blood culture samples | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of contamination rates by site of blood collection, volume of blood collected, provider of blood collection, and severity (APACHE [acute physiology and chronic health evaluation] II score, SOFA [sequential organ failure assessment] score) Safety endpoints: Adverse events (contact dermatitis, anaphylaxis, other) | — |
Contacts
Public ContactKohei Ota
Hiroshima University Hospital
Outcome results
None listed